FDA extends Entereg review period

Share this article:

The FDA will extend by three months the review time of GlaxoSmithKline and Adolor's jointly-developed post-operative ileus treatment Entereg.

A decision on the drug had been expected on Sunday. The agency now plans to review the drug until May 10.

In January, an FDA panel voted in favor of approving Entereg but said that Adolor needed to come up with a better plan to ensure the drug is not taken by patients on a long-term basis. Regulators have expressed concern over safety data that shows Entereg may hurt patients' cardiovascular system when taken over a long-term basis.

Adolor has submitted a new risk-management plan to the agency, which will account for the extra three months of review.

Post-operative ileus can affect patients after bowel surgery. Symptoms of the condition include constipation and other gastrointestinal dysfunction.

Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...